ATE491449T1 - Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien - Google Patents

Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien

Info

Publication number
ATE491449T1
ATE491449T1 AT06722337T AT06722337T ATE491449T1 AT E491449 T1 ATE491449 T1 AT E491449T1 AT 06722337 T AT06722337 T AT 06722337T AT 06722337 T AT06722337 T AT 06722337T AT E491449 T1 ATE491449 T1 AT E491449T1
Authority
AT
Austria
Prior art keywords
ornidazole
levo
anaerobic bacteria
anaerobic
racemic
Prior art date
Application number
AT06722337T
Other languages
English (en)
Inventor
Cang Zhang
Zaijin Teng
Li Li
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35304158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE491449(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE491449T1 publication Critical patent/ATE491449T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06722337T 2005-04-28 2006-04-17 Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien ATE491449T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100684789A CN1314396C (zh) 2005-04-28 2005-04-28 左旋奥硝唑在制备抗厌氧菌感染药物的应用
PCT/CN2006/000688 WO2006114042A1 (fr) 2005-04-28 2006-04-17 Application du levo-ornidazole dans la preparation d'un medicament anti-infections par des bacteries anaerobies

Publications (1)

Publication Number Publication Date
ATE491449T1 true ATE491449T1 (de) 2011-01-15

Family

ID=35304158

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06722337T ATE491449T1 (de) 2005-04-28 2006-04-17 Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien

Country Status (7)

Country Link
US (1) US8530507B2 (de)
EP (1) EP1875910B1 (de)
CN (1) CN1314396C (de)
AT (1) ATE491449T1 (de)
DE (1) DE602006018893D1 (de)
ES (1) ES2384451T3 (de)
WO (1) WO2006114042A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100451023C (zh) * 2006-01-06 2009-01-14 陕西新安医药科技有限公司 左旋奥硝唑磷酸酯及其制备方法和用途
CN1329379C (zh) * 2006-01-06 2007-08-01 沈阳中海生物技术开发有限公司 抗厌氧菌化合物
CN100368403C (zh) * 2006-01-06 2008-02-13 沈阳中海生物技术开发有限公司 一种抗厌氧菌化合物
CN100534429C (zh) * 2006-05-12 2009-09-02 南京圣和药业有限公司 左旋奥硝唑阴道给药制剂及其制备方法和制药用途
CN100503606C (zh) * 2006-05-24 2009-06-24 沈阳中海生物技术开发有限公司 噻二唑取代的咪唑类抗厌氧菌化合物
CN101279970B (zh) * 2007-04-05 2012-09-05 四川百利药业有限责任公司 2-甲基-5-硝基咪唑-1-(3-氯-2-羟基丙基)氯取代的衍生物、制备方法及其应用
WO2010146478A1 (en) * 2009-05-08 2010-12-23 Ranbaxy Laboratories Limited Parenteral composition comprising a fluoroquinolone compound and a nitroimidazole compound
CN102813622B (zh) * 2012-08-09 2013-06-26 西安万隆制药股份有限公司 一种奥硝唑氯化钠注射液组合物
CN104606187A (zh) * 2013-11-01 2015-05-13 南京圣和药业股份有限公司 左旋奥硝唑每日一次剂型
ES3035057T3 (en) * 2014-12-20 2025-08-28 John Malcolm Hall Gregg Ornidazole for use in treating infections caused by burkholderia mallei or burkholderia pseudomallei
CN107917979A (zh) * 2016-10-11 2018-04-17 陕西合成药业股份有限公司 一种分离分析左奥硝唑异构体的hplc方法
CN107224429B (zh) * 2017-06-21 2019-04-05 大连中信药业股份有限公司 一种安全性高的左旋奥硝唑注射液及其制备方法
CN107737099B (zh) * 2017-06-21 2019-06-28 大连中信药业股份有限公司 一种安全性高的左旋奥硝唑注射液及其制备方法
CN110538142A (zh) * 2018-05-29 2019-12-06 牛涛涛 一种抗感染药物注射液组合物
CN110538144A (zh) * 2019-06-13 2019-12-06 南京瓦尔生物医药有限公司 一种奥硝唑注射液和s-奥硝唑注射液
CN112569229A (zh) * 2019-09-29 2021-03-30 扬子江药业集团南京海陵药业有限公司 包含奥硝唑类化合物的制剂及其制备方法和用途
CN110538146A (zh) * 2019-10-08 2019-12-06 四川太平洋药业有限责任公司 一种左奥硝唑氯化钠注射液及制备工艺
CN112220747A (zh) * 2020-10-21 2021-01-15 山西普德药业有限公司 一种便于存储的奥硝唑注射液及其制备方法
CN115531306B (zh) * 2022-05-12 2024-03-26 南京锐志生物医药有限公司 一种注射用左奥硝唑衍生物乳状制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435049A (en) * 1965-05-19 1969-03-25 Hoffmann La Roche Nitroimidazole derivatives
CS238348B1 (sk) * 1983-11-14 1985-11-13 Timotej Putos Sposob odvodnenia zvodneného nadložia
MX9304399A (es) * 1992-07-31 1994-02-28 Warner Lambert Co Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
CN1212405C (zh) * 2002-08-23 2005-07-27 中国科学院上海有机化学研究所 外消旋奥硝唑的酶法拆分方法
CN1332662C (zh) * 2005-04-29 2007-08-22 南京圣和药业有限公司 左旋奥硝唑的静脉给药制剂及其制备方法
CN1739505A (zh) * 2005-09-19 2006-03-01 扬子江药业集团有限公司 一种左旋奥硝唑注射制剂
CN1739504A (zh) * 2005-09-19 2006-03-01 扬子江药业集团有限公司 一种左旋奥硝唑的制剂

Also Published As

Publication number Publication date
EP1875910A1 (de) 2008-01-09
WO2006114042A1 (fr) 2006-11-02
DE602006018893D1 (de) 2011-01-27
US20090326030A1 (en) 2009-12-31
EP1875910A4 (de) 2008-09-17
ES2384451T3 (es) 2012-07-05
EP1875910B1 (de) 2010-12-15
US8530507B2 (en) 2013-09-10
CN1314396C (zh) 2007-05-09
CN1686117A (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
ATE491449T1 (de) Anwendung von levo-ornidazol bei der herstellung eines medikaments gegen infektion mit anaeroben bakterien
HUS2000011I1 (hu) A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
ATE457310T1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007008618A3 (en) Sterilization using high-pressure carbon dioxide
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
TW200800970A (en) Novel cycloalkane carboxamides
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
WO2009003999A3 (en) Chemical compounds
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE524469T1 (de) Alkinylarylverbindungen und salze davon, diese enthaltende pharmazeutische zusammensetzungen, verfahren zu deren herstellung und deren verwendungen
SE0401970D0 (sv) Novel compounds
SG163540A1 (en) Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect
DE602004017777D1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
DE60316152D1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
EA200600778A1 (ru) 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами
ATE391730T1 (de) Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
DE602006019732D1 (de) Indolylmaleimidderivate
ATE435864T1 (de) Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2- aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
WO2008078453A1 (ja) 血小板産生促進因子及びその利用
WO2007006521A3 (en) Nutritional mixtures with a high and increased efficacy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties